TickerFacts.

NeuroSense Therapeutics Ltd. (NRSN): R&D Expense

Annual figures by period end, from SEC filings.

$6.23M
Year ended 2025-12-31
+3.7%
3-year compound annual growth
$7.27M2022-12-31: $5.59M2023-12-31: $7.27M2024-12-31: $5.70M2025-12-31: $6.23M$6.23M
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$6.23M+9.3%2026-03-31, From 2025-01-01
2024-12-31$5.70M-21.7%2026-03-31, From 2024-01-01
2023-12-31$7.27M+30.2%2026-03-31, From 2023-01-01
2022-12-31$5.59Mn/a2025-04-07, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
NeuroSense Therapeutics Ltd. (NRSN)2025-12-31$6.23M+9.3%
Ocean Biomedical, Inc. (OCEA)2024-12-31$26.0K-96.3%
Aspire Biopharma Holdings, Inc. (ASBP)2025-12-31$923.9K+540.0%
Semnur Pharmaceuticals, Inc. (SMNR)2025-12-31$2.55M+49.0%
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31$1.90M-7.5%
Accustem Sciences Inc. (ACUT)2025-12-31$281.0K+103.2%
Bioxytran, Inc (BIXT)2025-12-31$454.0K+304.1%
Alzamend Neuro, Inc. (ALZN)2026-04-30$3.63M+156.5%
ProtoKinetix, Inc. (PKTX)2025-12-31$106.6K+7.0%

Compare NRSN, OCEA, ASBP, SMNR side by side · Screen every company in Pharmaceutical Preparations ↗